Skip to main content
SpringerLink
Log in

Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

The aim of the present study was to assess whether quercetin exhibited any inhibitory effect on P-glycoprotein (P-gp)-mediated drug disposition in humans using fexofenadine as a P-gp substrate.

Methods

Twelve healthy subjects were enrolled in the study and treated daily for 7 days with 500 mg quercetin or placebo 3 times a day. On day 7, a single dose of 60 mg fexofenadine was administered orally. Plasma and urinary fexofenadine concentrations were measured, and pharmacokinetic differences between placebo and quercetin phases were assessed.

Results

The mean plasma concentrations of fexofenadine were significantly increased after quercetin treatment compared to those of the placebo phase. The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng·h/mL, P < 0.001) and similarly the maximum plasma concentration (Cmax) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006). Although the oral clearance of fexofenadine was decreased significantly by 37% after quercetin treatment (61.4 versus 38.7 L/h, P < 0.001), no differences in the renal clearance and half-life were observed between placebo and quercetin phases.

Conclusion

The results of the present study showed that short-term use of quercetin elevated the plasma concentrations of fexofenadine, probably by the inhibition of P-gp-mediated efflux in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Middleton E Jr (1998) Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 439:175–182

    PubMed  CAS  Google Scholar 

  2. Formica JV, Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33(12):1061–1080

    Article  PubMed  CAS  Google Scholar 

  3. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79(5):727–747

    PubMed  CAS  Google Scholar 

  4. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M et al (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34(6):459–464

    Article  PubMed  CAS  Google Scholar 

  5. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS (1998) Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 30(2):87–92

    PubMed  CAS  Google Scholar 

  6. Shapiro AB, Corder AB, Ling V (1997) P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 250(1):115–121

    Article  PubMed  CAS  Google Scholar 

  7. Eagling VA, Profit L, Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48(4):543–552

    Article  PubMed  CAS  Google Scholar 

  8. Choi JS, Li X (2005) Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. Int J Pharm 297(1–2):1–8

    PubMed  CAS  Google Scholar 

  9. Wang YH, Chao PD, Hsiu SL, Wen KC, Hou YC (2004) Lethal quercetin-digoxin interaction in pigs. Life Sci 74(10):1191–1197

    Article  PubMed  CAS  Google Scholar 

  10. Simpson K, Jarvis B (2000) Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59(2):301–321

    Article  PubMed  CAS  Google Scholar 

  11. Markham A, Wagstaff AJ (1998) Fexofenadine. Drugs 55(2):269–274 discussion 275–266

    Article  PubMed  CAS  Google Scholar 

  12. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T (1995) Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 34(2):92–95

    Article  PubMed  CAS  Google Scholar 

  13. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23(6):631–636

    PubMed  CAS  Google Scholar 

  14. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y (2006) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34(5):743–747

    Article  PubMed  CAS  Google Scholar 

  15. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27(8):866–871

    PubMed  CAS  Google Scholar 

  16. Perloff MD, von Moltke LL, Greenblatt DJ (2002) Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 42(11):1269–1274

    Article  PubMed  CAS  Google Scholar 

  17. Kim KA, Park PW, Kim HK, Ha JM, Park JY (2005) Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol 45(8):941–946

    Article  PubMed  CAS  Google Scholar 

  18. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78(2):191–201

    Article  PubMed  CAS  Google Scholar 

  19. Uno T, Shimizu M, Sugawara K, Tateishi T (2006) Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 34(11):1875–1879

    Article  PubMed  CAS  Google Scholar 

  20. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW (2006) Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46(7):758–767

    Article  PubMed  Google Scholar 

  21. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD (2002) Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71(6):414–420

    Article  PubMed  CAS  Google Scholar 

  22. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69(3):114–121

    Article  PubMed  CAS  Google Scholar 

  23. Choi JS, Choi BC, Choi KE (2004) Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm 61(22):2406–2409

    PubMed  CAS  Google Scholar 

  24. Patel J, Buddha B, Dey S, Pal D, Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11(4):262–277

    Article  PubMed  Google Scholar 

  25. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68(6):598–604

    Article  PubMed  CAS  Google Scholar 

  26. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H, Sawada Y (2000) Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 395(3):193–201

    Article  PubMed  CAS  Google Scholar 

  27. Kim KA, Park JY, Lee JS, Lim S (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26(8):631–637

    Article  PubMed  CAS  Google Scholar 

  28. Kim KA, Chung J, Jung DH, Park JY (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60(8):575–581

    Article  PubMed  CAS  Google Scholar 

  29. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF (1993) Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 36(5):460–463

    PubMed  CAS  Google Scholar 

  30. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308(2):438–445

    Article  PubMed  Google Scholar 

  31. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71(1):11–20

    Article  PubMed  CAS  Google Scholar 

  32. Dresser GK, Kim RB, Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77(3):170–177

    Article  PubMed  CAS  Google Scholar 

  33. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF (2005) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59(5):602–604

    Article  PubMed  CAS  Google Scholar 

  34. Wang X, Wolkoff AW, Morris ME (2005) Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33(11):1666–1672

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the Korea University Research Fund in 2006 and a grant of the Korea Health 21 R&D Project, Ministry for Health, Welfare and Family Affairs, R.O.K. (A030001).

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Sungbuk-gu, Seoul, 136-705, Korea

    Kyoung-Ah Kim & Ji-Young Park

  2. Department of Laboratory Medicine, Gil Medical Center, Gachon Medical School, Incheon, Korea

    Pil-Whan Park

Authors
  1. Kyoung-Ah Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pil-Whan Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ji-Young Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ji-Young Park.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, KA., Park, PW. & Park, JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 65, 609–614 (2009). https://doi.org/10.1007/s00228-009-0627-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0627-6

Keywords

Search

Navigation